Showing 13 to 24 of 52 results
Camizestrant Shows Significant Promise in Treating Aggressive Breast Cancer
A clinical trial shows that the drug camizestrant significantly reduces the risk of progression or death in patients with HR-positive HER2-negative breast cancer who have the ESR1 mutation, a common cause of treatment resistance; the drug is being fast-tracked for approval in the US and UK.
Camizestrant Shows Significant Promise in Treating Aggressive Breast Cancer
A clinical trial shows that the drug camizestrant significantly reduces the risk of progression or death in patients with HR-positive HER2-negative breast cancer who have the ESR1 mutation, a common cause of treatment resistance; the drug is being fast-tracked for approval in the US and UK.
Progress
56% Bias Score
CRISPR Gene Editing Shows Promise in Treating Rare Infant Disorder
A six-month-old American baby with severe carbamoyl phosphate synthetase 1 (CPS1) deficiency, a rare genetic disorder affecting approximately one in a million infants, received a custom CRISPR gene-editing therapy resulting in a reduction of medication dependency and improved health.
CRISPR Gene Editing Shows Promise in Treating Rare Infant Disorder
A six-month-old American baby with severe carbamoyl phosphate synthetase 1 (CPS1) deficiency, a rare genetic disorder affecting approximately one in a million infants, received a custom CRISPR gene-editing therapy resulting in a reduction of medication dependency and improved health.
Progress
36% Bias Score
Regeneron Acquires Bankrupt 23andMe for $256 Million
Regeneron Pharmaceuticals will acquire the bankrupt DNA testing firm 23andMe for $256 million, despite earlier concerns about data security and privacy raised by US state attorneys general, who sought an ombudsman to oversee data protection. Regeneron plans to use 23andMe's data for drug development...
Regeneron Acquires Bankrupt 23andMe for $256 Million
Regeneron Pharmaceuticals will acquire the bankrupt DNA testing firm 23andMe for $256 million, despite earlier concerns about data security and privacy raised by US state attorneys general, who sought an ombudsman to oversee data protection. Regeneron plans to use 23andMe's data for drug development...
Progress
40% Bias Score
Successful Gene Editing Treats Rare Genetic Disease in Baby
A baby with severe CPS1 deficiency, a rare genetic disorder affecting approximately one in a million infants, received a custom gene-editing therapy using CRISPR base editing, resulting in significant health improvements within months, opening possibilities for treating other rare genetic diseases.
Successful Gene Editing Treats Rare Genetic Disease in Baby
A baby with severe CPS1 deficiency, a rare genetic disorder affecting approximately one in a million infants, received a custom gene-editing therapy using CRISPR base editing, resulting in significant health improvements within months, opening possibilities for treating other rare genetic diseases.
Progress
40% Bias Score
Gene Editing Successfully Treats Baby's Life-Threatening Genetic Disorder
Doctors successfully used a personalized gene-editing therapy to treat baby KJ Muldoon's life-threatening genetic disorder, carbamoyl phosphate synthetase 1 (CPS1), showing potential for treating numerous rare diseases previously untreatable.
Gene Editing Successfully Treats Baby's Life-Threatening Genetic Disorder
Doctors successfully used a personalized gene-editing therapy to treat baby KJ Muldoon's life-threatening genetic disorder, carbamoyl phosphate synthetase 1 (CPS1), showing potential for treating numerous rare diseases previously untreatable.
Progress
40% Bias Score
Personalized Gene Therapy Shows Promise in Treating Baby with Rare Metabolic Disorder
In February 2025, a baby born with a life-threatening metabolic disorder received a personalized gene therapy in the US, showing significant health improvements and enabling the baby to return home, representing a potential breakthrough for treating rare genetic diseases with personalized base editi...
Personalized Gene Therapy Shows Promise in Treating Baby with Rare Metabolic Disorder
In February 2025, a baby born with a life-threatening metabolic disorder received a personalized gene therapy in the US, showing significant health improvements and enabling the baby to return home, representing a potential breakthrough for treating rare genetic diseases with personalized base editi...
Progress
40% Bias Score
EMA Conditionally Approves Ocatazil for Relapsed/Refractory ALL
The European Medicines Agency (EMA) conditionally approved Ocatazil, a CAR-T cell therapy, for adults (≥26) with relapsed or refractory acute lymphoblastic leukemia (ALL), based on a Phase 2 trial showing 64% complete response rate (n=113) with a median duration of 14 months; however, serious side e...
EMA Conditionally Approves Ocatazil for Relapsed/Refractory ALL
The European Medicines Agency (EMA) conditionally approved Ocatazil, a CAR-T cell therapy, for adults (≥26) with relapsed or refractory acute lymphoblastic leukemia (ALL), based on a Phase 2 trial showing 64% complete response rate (n=113) with a median duration of 14 months; however, serious side e...
Progress
40% Bias Score
ChemoID Test Significantly Improves Outcomes for Platinum-Resistant Ovarian Cancer
A phase 3 clinical trial published in Nature Partner Journal "Precision Oncology" demonstrates that the ChemoID test, analyzing tumor stem cells to guide chemotherapy selection, significantly improves response rates (50% vs 5%) and progression-free survival (11 months vs 3 months) in patients with p...
ChemoID Test Significantly Improves Outcomes for Platinum-Resistant Ovarian Cancer
A phase 3 clinical trial published in Nature Partner Journal "Precision Oncology" demonstrates that the ChemoID test, analyzing tumor stem cells to guide chemotherapy selection, significantly improves response rates (50% vs 5%) and progression-free survival (11 months vs 3 months) in patients with p...
Progress
48% Bias Score
Gene Editing Successfully Treats Baby's Life-Threatening Disorder
Doctors successfully treated a baby born with a life-threatening urea cycle disorder using a custom gene-editing therapy in Philadelphia, marking a major breakthrough in personalized medicine; the therapy appears to be working, allowing the baby to eat more protein, gain weight, and reach developmen...
Gene Editing Successfully Treats Baby's Life-Threatening Disorder
Doctors successfully treated a baby born with a life-threatening urea cycle disorder using a custom gene-editing therapy in Philadelphia, marking a major breakthrough in personalized medicine; the therapy appears to be working, allowing the baby to eat more protein, gain weight, and reach developmen...
Progress
40% Bias Score
Gene Editing Successfully Treats Rare Genetic Disease in Infant
A baby, K.J. Muldoon, born with severe CPS1 deficiency, a rare genetic disease affecting approximately one in a million infants, is thriving after receiving a custom CRISPR-based gene-editing therapy developed by the Children's Hospital of Philadelphia and Penn Medicine, offering hope for millions w...
Gene Editing Successfully Treats Rare Genetic Disease in Infant
A baby, K.J. Muldoon, born with severe CPS1 deficiency, a rare genetic disease affecting approximately one in a million infants, is thriving after receiving a custom CRISPR-based gene-editing therapy developed by the Children's Hospital of Philadelphia and Penn Medicine, offering hope for millions w...
Progress
48% Bias Score
Successful Gene Editing Therapy Treats Rare Genetic Disorder in Baby
A baby with CPS1 deficiency, a rare genetic disease affecting approximately one in a million infants, successfully underwent a custom gene-editing therapy using base editing, resulting in significant improvement in his health within months.
Successful Gene Editing Therapy Treats Rare Genetic Disorder in Baby
A baby with CPS1 deficiency, a rare genetic disease affecting approximately one in a million infants, successfully underwent a custom gene-editing therapy using base editing, resulting in significant improvement in his health within months.
Progress
40% Bias Score
Personalized Gene Editing Shows Promise in Treating Rare Metabolic Disorder
A US baby, KJ, diagnosed with the ultra-rare CPS1 deficiency, received a groundbreaking personalized gene-editing therapy using base editors, showing promising results and offering a new hope for treating such rare metabolic disorders. The treatment was delivered in two doses via lipid nanoparticles...
Personalized Gene Editing Shows Promise in Treating Rare Metabolic Disorder
A US baby, KJ, diagnosed with the ultra-rare CPS1 deficiency, received a groundbreaking personalized gene-editing therapy using base editors, showing promising results and offering a new hope for treating such rare metabolic disorders. The treatment was delivered in two doses via lipid nanoparticles...
Progress
40% Bias Score
Showing 13 to 24 of 52 results